



HEMODIALYSIS ACCESS MANAGEMENT SOLUTIONS WHATEVER ROUTE YOU TAKE...



ACCESS



TREAT



SUSTAIN




...MAKE A LASTING IMPACT



SUPER SHEATH™

Introducer Sheath



SMOOTH TRANSITIONS – TOTAL PERFORMANCE

**FOCUSED DESIGN FOR EASE OF
ENTRY AND REDUCED TRAUMA***

EXCELLENT
DEVICE
PASSAGE



EFFICIENT
OPERATION




SMOOTH
TRANSITIONS



STARTER™

Guide Wire




ZIPWIRE™

Hydrophilic Guide Wire



IMAGER™ II

4F Angiographic Catheter



ACCESS
and diagnose

* Bench testing performed by Togo Medikit Co., Ltd. Data on file.



ANGIOJET™

Thrombectomy System

CLEARs THROMBUS. RIGHT, FROM THE START


AngioJet combines mechanical thrombectomy with Power Pulse™ for rapid thrombus removal. This highly effective combination can often mean faster restoration of flow, reduced lytic needed, and may shorten treatment time.¹




QUICK THROMBUS RESOLUTION IN AV ACCESS CONDUITS

Thrombus narrowing or restricting flow within AV access fistulas and grafts can prevent a patient from undergoing life supportive dialysis treatment.

AngioJet is designed to offer quick removal of thrombotic materials from the dialysis access conduit, potentially improving long-term patency.



Pre-procedure: AngioJet catheter positioned in thrombosed AV graft.



Post-procedure: Imaging post-AngioJet System activation in both venous and arterial side of AV graft.

TREAT
the thrombus


1. The PEARL Registry study

ANGIOJET™

Thrombectomy System

PEARL REGISTRY DEMONSTRATES NEARLY DOUBLE THE PATENCY

Results in AV Conduits¹
N = 145 patients



KDOQI: Kidney Disease Outcomes Quality Initiative

1. Presented by Dr. Eugene Simoni at VEITH 2013; Final PEARL Data Aug 2013 Simoni.
PEARL Registry Hemodialysis Access. VEITH 2013

TREAT
the thrombus



MUSTANG™

0.035" Balloon Dilation Catheter




TREAT

the stenosis

EXCELLENCE ON EVERY DIMENSION ONLY ONE BALLOON PROVIDES TOTAL PERFORMANCE

With superior cross and track, powerful dilatation, longer lengths, and smaller sheath sizes, Mustang is the 0.035" (0.89mm) workhorse balloon that offers excellence across the board.

DELIVERABLE HIGH PRESSURE



LOW PROFILE




BROADEST SIZE MATRIX



ATHLETIS™

Ultra-High-Pressure PTA Balloon

NEW



The braiding matrix was designed using a liquid-crystal polymer material that was used by NASA in the Mars Rover parachute.

OPTIMISED DELIVERABILITY TO REACH AND TREAT CHALLENGING LESIONS

With an ideal blend of track and a low crossing profile, Athletis is designed to reach highly calcified, long, stenotic, or resistant fibrotic lesions, including those commonly found in AV access procedures.

ULTRA-HIGH PRESSURE

Athletis' proprietary braided balloon design enables optimised deliverability and ultra-high pressures up to 40 ATM. The unique, non-compliant balloon design enables Athletis to open to the stated diameter even in highly resistant lesions.

ULTRA-LOW PROFILE

Athletis features a class-leading low lesion entry profile with an 0.042" flexible, tapered tip over an 0.035" guidewire.

42%
LOWER

ATHLETIS
0.042"

TIP PROFILE COMPARED
TO COMPETITOR

COMPETITOR
0.072"*



TREAT

the stenosis



*Average measurements taken by Boston Scientific. Data on file (TR 92200478). Bench test results may not necessarily be indicative of clinical performance.



ATHLETIS™

Ultra-High-Pressure PTA Balloon



NEW




TREAT

the stenosis

ATHLETIS: REAL-WORLD CASES, REAL-WORLD IMPACT




Case 1: Lesion location: Brachiocephalic and superior vena cava – Athletis 12x40



Case 2: Lesion location: Subclavian and basilic vein – Athletis 12x40

Images courtesy of Drs Markus Schmidt and Michael Popp,
Klinikum Bad Hersfeld in Germany.

PERIPHERAL CUTTING BALLOON™




MICROSURGICAL DILATATION DEVICE FOR HEMODIALYSIS ACCESS MANAGEMENT

ATHEROTOMES

Microsurgical blades designed to create precise incisions

NON-COMPLIANT BALLOON MATERIAL

Designed for predictable, controlled dilatation



CUTTING BALLOON™ ANGIOPLASTY

- 6-10 ATM
- Focuses the dilatation force at the tips of the atherotomes
- Designed to score, then gently dilate the lesion, minimising barotrauma
- Propagates controlled plaque disruption through lesion
- Theoretical hoop stress relief and disruption of elastic and fibrotic continuity that causes recoil


TREAT

the stenosis



RANGER™

Paclitaxel-Coated PTA Balloon Catheter



SUSTAIN

the patency

PROVEN TECHNOLOGY

SUPPORTED BY UNPARALLELED CLINICAL EVIDENCE

- Built on market-leading Sterling™ balloon platform
- Designed to:
 - minimise downstream particulates while maximising effectiveness and durability
 - offer efficient drug-transfer and low drug dose ($2\mu\text{g}/\text{mm}^2$)
- Broad diameter matrix (4-7mm) and lengths out to 200mm



COMPARE

HEAD-TO-HEAD CLINICAL TRIAL 12-MONTH DATA¹

RANGER
DCB



IN.PACT
DCB

SIMILAR PATENCY

SIMILAR FREEDOM FROM TARGET LESION
REVASCULARISATION (FTLR)

2
 $\mu\text{g}/\text{mm}^2$

Achieved with
**SIGNIFICANTLY
LESS DRUG**

3.5
 $\mu\text{g}/\text{mm}^2$

1. COMPARE Clinical Trial 12-Month Results presented by Sabine Steiner, MD. LINC 2020. 12-Month Primary Endpoints: Binary Primary Patency = 83.0% for Ranger DCB and 81.5% for IN.PACT DCB (Pnon-inferiority <0.01). Freedom from Major Adverse Events = 91.0% for Ranger DCB and 92.6% for IN.PACT DCB (Pnon-inferiority <0.01)





**Boston
Scientific**
Advancing science for life™

All cited trademarks are the property of their respective owners. CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labelling supplied with each device. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.

2020 Copyright
© Boston Scientific Corporation
or its affiliates. All rights reserved.
PI- 905603-AB

